Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, November 8, 2022
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
Matthew Harrison Maintained (TSVT) at Buy with Increased Target to $29 on, Nov 8th, 2022
Matthew Harrison of Morgan Stanley, Maintained "2seventy bio, Inc." (TSVT) at Buy with Increased Target from $27 to $29 on, Nov 8th, 2022.
Matthew has made no other calls on TSVT in the last 4 months.
There is 1 other peer that has a rating on TSVT. Out of the 1 peers that are also analyzing TSVT, 0 agree with Matthew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Matthew
- Kelsey Goodwin of "Guggenheim" Initiated at Strong Buy and Held Target at $30 on, Monday, October 31st, 2022
